Results 171 to 180 of about 31,219 (282)

Recurrent haemorrhage, due to vitamin K‐dependent coagulopathy, as the primary presenting complaint in a dog with naturally occurring hypoadrenocorticism

Veterinary Record Case Reports, Volume 14, Issue 1, February 2026.
Abstract A 5‐year‐old male neutered standard poodle, presented with recurrent gingival margin haemorrhage and associated prolongations in prothrombin time and activated partial thromboplastin time, with repeatable demonstration of clinical (bleeding) and laboratory (prothrombin time, activated partial thromboplastin time) resolution with, and relapse ...
Jenny Reeve, Aiden Pang
wiley   +1 more source

Antagonism of Kinin Receptors B1 and B2 Attenuates Folic Acid‐Induced Tubulointerstitial Fibrosis in Mice

Basic &Clinical Pharmacology &Toxicology, Volume 138, Issue 2, February 2026.
ABSTRACT Chronic kidney disease (CKD) remains a significant global health burden despite recent advances in pharmacotherapy, including sodium‐glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists. Renal fibrosis, a central pathological hallmark of CKD progression, is mediated by persistent inflammation and macrophage ...
Gabriel Rufino Estrela, Alexandre Budu, Juliene Silva, Raisa Brito, Frederick Wasinski, Jonatan Barrera‐Chimal, Ronaldo Carvalho Araujo   +6 more
wiley   +1 more source

Endocrine consequences of antifungal therapy: A missed entity. [PDF]

World J Clin Cases
Thakkar S, Kantroo V, Nagendra L, Dutta D, Kamrul-Hasan ABM, Kalra S, Bhattacharya S.   +6 more
europepmc   +1 more source

A Retrospective Study on the Impact of Primary Aldosteronism in Pregnancy (H.A.P.P.I. Study Group)

Clinical Endocrinology, Volume 104, Issue 2, Page 113-122, February 2026.
ABSTRACT Objective Primary aldosteronism (PA) is a common cause of hypertension in young women. However, there is a paucity of data regarding its impact during pregnancy. The primary objective of this study was to describe the occurrence of hypertensive disorders of pregnancy (HDP) in PA.
Diana Oprea, Frédérique Lefrançois, Matthieu St‐Jean, Anne‐Marie Côté, Marie‐Ève Roy‐Lacroix, Mandy Malick, Pierre‐Luc Mallet, Nadine Sauvé   +7 more
wiley   +1 more source

Population-based estimates of the global prevalence and carrier frequency of apparent mineralocorticoid excess caused by 11β-hydroxysteroid dehydrogenase type 2 deficiency. [PDF]

Orphanet J Rare Dis
Charoenngam N, Kansuttiviwat C, Chinsawangwatanakul P.   +2 more
europepmc   +1 more source

Steroids:Modulators of inflammation and immunity [PDF]

, 2010
Chapman, Karen E, Odermatt, Alex
core   +1 more source

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1490-1498, February 2026.
Abstract Aims Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in ...
Sean Wharton, Carel W. le Roux, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

Exogenous corticosteroid-induced modulation of RAAS: potential implications for septic shock biomarker analysis. [PDF]

Ann Intensive Care
Uslar T, Sanfuentes B, Baudrand R, Hernández G, Kattan E.   +4 more
europepmc   +1 more source

Hormones and nocturia : guidelines for medical treatment? [PDF]

, 2014
Everaert, Karel, Goessaert, An-Sofie, Kapila, Ayush, Vande Walle, Johan   +3 more
core   +1 more source

Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1105-1115, February 2026.
Abstract Background Albuminuria is associated with an increased risk of cardiovascular and kidney events. Sodium glucose co‐transporter 2 inhibitors (SGLT2i) reduce albuminuria and improve kidney outcomes in patients with albuminuric chronic kidney disease (CKD).
João Pedro Ferreira, Pedro Marques, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Abhinav Sharma, Francisco Vasques‐Nóvoa, Luís Mendonça, João Sérgio Neves, Milton Packer, Faiez Zannad   +10 more
wiley   +1 more source